BAYRY
A tiny target bump, a big legal shadow
Goldman Sachs just nudged Bayer’s price target up to €55 from €54 and kept the stock on Buy. Not exactly a fireworks display, but in analyst-land that’s basically a polite nod and a fresh cup of coffee.
Why the market should care
The bigger headline is what Goldman thinks is coming next: first-quarter earnings may come in ahead of market expectations when Bayer reports in mid-May. For a company that’s been juggling legal headaches, any hint of upside is welcome — even if it comes with the emotional support of a very large asterisk.
The courtroom still has center stage
Analyst James Quigley also pointed investors back to the Durnell case. The upcoming oral hearing before the U.S. Supreme Court is still the main event, and for Bayer, legal risk remains the thing that can move the stock faster than a spreadsheet ever will.
- Slightly higher price target: €55
- Buy rating stays intact
- Q1 earnings could beat expectations
- Supreme Court hearing remains the overhang
Big picture
This is less “new thesis, new era” and more “we still like the setup, but the lawsuit cloud is not going anywhere.” For investors, Bayer is still a story about whether the operating business can outrun the legal baggage.